On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
You may also be interested in...
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.